theMednetRegister
  • Community
    • Overview
    • Experts
    • Editors
    • Fellows
    • Code of conduct
    • AI Guidelines for Physicians
  • Company
    • About Us
    • FAQs
    • Privacy Policy
    • Terms of Use
    • Careers
    • Programs
  • News
    • News Releases
    • Press Coverage
    • Publications
    • Blog
  • Contact Us
  • Sign in

Pediatric Hematology/Oncology

Follicular Lymphoma   

Questions discussed in this category


What are your top takeaways in Hematologic Malignancies from ASH 2024?
12 Answers available

What are your top takeaways in Lymphoma from ASH 2025?
3 Answers available
2245426899


Papers discussed in this category


Cancer, 2023 Jun 24
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.

The New England journal of medicine, 2024 Jun 03
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Nature medicine, 2024 Jun 03
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.

Lancet (London, England), 2025 Dec 07
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.

Lancet (London, England), 2025 Dec 05
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.

The New England journal of medicine, 2025 Dec 06
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Related Topics in Pediatric Hematology/Oncology

  • Lung Cancer
  • Breast Cancer
  • Head and Neck Cancers
  • Hematologic Malignancies
  • Radiation Oncology
  • Gynecologic Oncology
  • Palliation
  • Neuro-Oncology
  • Gastrointestinal Cancers
  • Genitourinary Cancers

Copyright © 2026 theMednet
All Rights Reserved.